Experimental brain tumor therapy offered before approval

NCT ID NCT07497984

Summary

This program provides eligible patients with access to an investigational drug called ITM11 for treating meningioma, a type of brain tumor, before it is officially approved. A treating doctor must decide if the potential benefits for an individual patient outweigh the risks of using an unapproved therapy. The program's availability depends on the patient's country and specific eligibility criteria.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.